As Vertex Pharmaceuticals (VRTX) Market Valuation Rose, Clough Capital Partners LP Raised Position by $417,200; Computer Programs & Systems (CPSI) Valuation Declined While Stadium Capital Management Has Decreased Stake by $17.43 Million

May 26, 2018 - By Winifred Garcia

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

Charles Clough increased its stake in Vertex Pharmaceuticals Inc (VRTX) by 4.45% based on its latest 2017Q4 regulatory filing with the SEC. Clough Capital Partners LP bought 2,800 shares as the company’s stock rose 6.91% while stock markets declined. The hedge fund run by Charles Clough held 65,682 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $9.84 million, up from 62,882 at the end of the previous reported quarter. Clough Capital Partners LP who had been investing in Vertex Pharmaceuticals Inc for a number of months, seems to be bullish on the $40.14 billion market cap company. The stock increased 0.34% or $0.53 during the last trading session, reaching $157.5. About 560,980 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 76.59% since May 26, 2017 and is uptrending. It has outperformed by 65.04% the S&P500.

Alexander Medina Seaver decreased its stake in Computer Programs & Systems Inc (CPSI) by 46.49% based on its latest 2017Q4 regulatory filing with the SEC. Stadium Capital Management Llc sold 581,148 shares as the company’s stock declined 0.76% with the market. The hedge fund run by Alexander Medina Seaver held 668,933 shares of the technology company at the end of 2017Q4, valued at $20.10M, down from 1.25 million at the end of the previous reported quarter. Stadium Capital Management Llc who had been investing in Computer Programs & Systems Inc for a number of months, seems to be less bullish one the $439.64 million market cap company. The stock increased 2.84% or $0.9 during the last trading session, reaching $32.55. About 276,672 shares traded or 205.71% up from the average. Computer Programs and Systems, Inc. (NASDAQ:CPSI) has risen 5.42% since May 26, 2017 and is uptrending. It has underperformed by 6.13% the S&P500.

Investors sentiment decreased to 1.34 in Q4 2017. Its down 0.28, from 1.62 in 2017Q3. It dropped, as 53 investors sold VRTX shares while 160 reduced holdings. 72 funds opened positions while 213 raised stakes. 232.48 million shares or 0.46% more from 231.42 million shares in 2017Q3 were reported. Prudential Pcl has 1,813 shares. Connor Clark And Lunn Invest Mgmt owns 13,425 shares for 0.01% of their portfolio. Ajo Limited Partnership has 0.36% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). First Manhattan Company stated it has 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Aqr Cap Mgmt Limited holds 0.24% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 1.52M shares. 18,475 are owned by Sumitomo Mitsui Asset Communication Ltd. Sectoral Asset Mgmt Incorporated stated it has 36,715 shares. Axa owns 262,114 shares. Stifel Fincl reported 66,644 shares or 0.03% of all its holdings. Clough Prtnrs LP owns 0.82% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 65,682 shares. Silvercrest Asset Management Grp Ltd Liability Co reported 10,023 shares. Cornerstone Mngmt Hldg Limited Liability invested in 0.05% or 47,549 shares. Kbc Gp Nv, a Belgium-based fund reported 22,728 shares. Group Inc One Trading Limited Partnership stated it has 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Bailard, California-based fund reported 2,200 shares.

Clough Capital Partners L P, which manages about $5.01 billion and $1.20 billion US Long portfolio, decreased its stake in Ladder Cap Corp (NYSE:LADR) by 54,700 shares to 742,078 shares, valued at $10.12M in 2017Q4, according to the filing. It also reduced its holding in Ares Cap Corp (NASDAQ:ARCC) by 333,400 shares in the quarter, leaving it with 2.51 million shares, and cut its stake in Microsoft Corp (NASDAQ:MSFT).

Since December 11, 2017, it had 0 insider buys, and 50 sales for $106.45 million activity. On Monday, February 12 Sachdev Amit sold $2.68M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 17,796 shares. Another trade for 98 shares valued at $15,266 was made by ALTSHULER DAVID on Tuesday, May 15. Chodakewitz Jeffrey sold $772,493 worth of stock. 4,044 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $614,001 were sold by Arbuckle Stuart A. $3.25M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by MCGLYNN MARGARET G. LEIDEN JEFFREY M sold $17.67 million worth of stock or 125,000 shares.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Seekingalpha.com which released: “Vertex Hits Stumbling Block For One Triple-Combo Therapy For Cystic Fibrosis” on April 30, 2018, also Seekingalpha.com with their article: “Vertex Pharmaceuticals Heads Toward An Important Tipping Point” published on May 01, 2018, Streetinsider.com published: “Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies – RBC” on May 15, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Investorplace.com and their article: “The 10 Fastest-Growing Stocks to Invest In Right Now” published on May 22, 2018 as well as Streetinsider.com‘s news article titled: “Vertex Pharma (VRTX) Still Looks Best Positioned After CF Deep Dive – JPMorgan” with publication date: May 18, 2018.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals had 102 analyst reports since July 31, 2015 according to SRatingsIntel. Oppenheimer upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Sunday, July 9. Oppenheimer has “Buy” rating and $15000 target. The stock has “Overweight” rating by Morgan Stanley on Friday, April 27. The firm has “Buy” rating given on Friday, September 15 by Needham. The stock has “Neutral” rating by Goldman Sachs on Thursday, April 28. The company was upgraded on Thursday, February 1 by Barclays Capital. The rating was upgraded by Oppenheimer on Thursday, February 1 to “Buy”. The firm has “Buy” rating given on Wednesday, January 31 by Jefferies. The firm has “Buy” rating given on Thursday, February 4 by Argus Research. On Sunday, August 20 the stock rating was maintained by Jefferies with “Buy”. Oppenheimer initiated the stock with “Perform” rating in Thursday, December 15 report.

Since March 12, 2018, it had 0 insider buys, and 9 selling transactions for $1.12 million activity. Another trade for 1,252 shares valued at $36,621 was sold by Fowler Christopher L. The insider DYE DAVID A sold $148,600. Chambless Matt J also sold $172,668 worth of Computer Programs and Systems, Inc. (NASDAQ:CPSI) on Tuesday, May 15. $122,029 worth of Computer Programs and Systems, Inc. (NASDAQ:CPSI) was sold by SCHNEIDER VICTOR S on Thursday, March 15. The insider Rosser Troy D sold $287,449.

Among 14 analysts covering Computer Progams & Systems (NASDAQ:CPSI), 3 have Buy rating, 2 Sell and 9 Hold. Therefore 21% are positive. Computer Progams & Systems had 38 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Computer Programs and Systems, Inc. (NASDAQ:CPSI) earned “Sector Perform” rating by RBC Capital Markets on Monday, November 30. The firm has “Hold” rating given on Tuesday, December 1 by Deutsche Bank. The firm has “Sell” rating by Deutsche Bank given on Friday, August 5. The firm has “Hold” rating by Topeka Capital Markets given on Monday, November 30. The stock of Computer Programs and Systems, Inc. (NASDAQ:CPSI) has “Hold” rating given on Thursday, November 2 by Cantor Fitzgerald. SunTrust upgraded the shares of CPSI in report on Monday, December 14 to “Buy” rating. Robert W. Baird maintained it with “Hold” rating and $30.0 target in Thursday, August 31 report. As per Tuesday, January 30, the company rating was maintained by KeyBanc Capital Markets. The company was maintained on Thursday, February 4 by KeyBanc Capital Markets. The company was maintained on Friday, January 29 by RBC Capital Markets.

Analysts await Computer Programs and Systems, Inc. (NASDAQ:CPSI) to report earnings on August, 2. They expect $0.48 EPS, up 37.14% or $0.13 from last year’s $0.35 per share. CPSI’s profit will be $6.48 million for 16.95 P/E if the $0.48 EPS becomes a reality. After $0.47 actual EPS reported by Computer Programs and Systems, Inc. for the previous quarter, Wall Street now forecasts 2.13% EPS growth.

More important recent Computer Programs and Systems, Inc. (NASDAQ:CPSI) news were published by: Prnewswire.com which released: “EU’s $24 Billion AI Investment Signals Healthcare Big Data Boom” on May 24, 2018, also Businesswire.com published article titled: “Product Vision Takes Center Stage at the CPSI 2018 National Client Conference”, Businesswire.com published: “CPSI and Alliance Health Partners Announce Partnership” on May 24, 2018. More interesting news about Computer Programs and Systems, Inc. (NASDAQ:CPSI) was released by: Seekingalpha.com and their article: “Computer Programs & Systems (CPSI) Q1 2018 Results – Earnings Call Transcript” with publication date: May 04, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>